Acute pulmonary hypertension is a life threatening is a life-threatening condition, where the lungs’ vessels contract, which means that the heart does not have the ability to pump the blood through the lungs. Attgeno´s molecule, Supernitro (PDNO), is based on a body-like substance, lowers the pressure in the lungs and could thus save many lives. The pressure in the lungs also almost always increases after major surgery, when the patient is lying in the heart-lung machine. This is a major clinical problem and it is the body’s own defense that causes it. Through the support from Swelife, Attgeno and Swetox are now conducting a preclinical safety evaluation. During 2019-2020, clinical trials can be started and within about three years, the first clinical trials on patients can be completed.